Hepatitis C virus-induced hepatocellular carcinoma.
10.3350/cmh.2015.21.2.105
- Author:
Nicolas GOOSSENS
1
;
Yujin HOSHIDA
Author Information
1. Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. yujin.hoshida@mssm.edu
- Publication Type:Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
- Keywords:
Carcinogenesis;
Hepatitis C;
Hepatocellular carcinoma;
Prevention
- MeSH:
Biomarkers, Tumor/genetics/metabolism;
Carcinoma, Hepatocellular/*etiology;
Hepacivirus/genetics/*pathogenicity;
Hepatitis C/complications/pathology/virology;
Humans;
Liver Neoplasms/*etiology;
Risk
- From:Clinical and Molecular Hepatology
2015;21(2):105-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hepatitis C virus (HCV) is a leading etiology of hepatocellular carcinoma (HCC). The interaction of HCV with its human host is complex and multilayered; stemming in part from the fact that HCV is a RNA virus with no ability to integrate in the host's genome. Direct and indirect mechanisms of HCV-induced HCC include activation of multiple host pathways such as liver fibrogenic pathways, cellular and survival pathways, interaction with the immune and metabolic systems. Host factors also play a major role in HCV-induced HCC as evidenced by genomic studies identifying polymorphisms in immune, metabolic, and growth signaling systems associated with increased risk of HCC. Despite highly effective direct-acting antiviral agents, the morbidity and incidence of liver-related complications of HCV, including HCC, is likely to persist in the near future. Clinical markers to selectively identify HCV subjects at higher risk of developing HCC have been reported however they require further validation, especially in subjects who have experienced sustained virological response. Molecular biomarkers allowing further refinement of HCC risk are starting to be implemented in clinical platforms, allowing objective stratification of risk and leading to individualized therapy and surveillance for HCV individuals. Another role for molecular biomarker-based stratification could be enrichment of HCC chemoprevention clinical trials leading to smaller sample size, shorter trial duration, and reduced costs.
